Long-acting GHRH analogue with Drug Affinity Complex (DAC) modification. Creates sustained GH pulse elevation through extended half-life via albumin binding.
CJC-1295 with DAC (Drug Affinity Complex) is a modified version of growth hormone releasing hormone (GHRH) that has been engineered to last much longer than natural GHRH — approximately one to two weeks per injection. It was developed by ConjuChem and studied in human phase 1 and 2 trials. It stimulates the pituitary to produce more growth hormone over an extended period.
Growth Hormone Research
CJC-1295 with DAC was studied in healthy adults in phase 1 and 2 trials. The trials demonstrated that it produced sustained elevations in growth hormone and IGF-1 levels over days following a single injection, validating the extended half-life design. Doses of 1-2mg every 1-2 weeks produced meaningful GH/IGF-1 changes.
Body Composition Research
Phase 2 trials examined effects on lean body mass and fat mass over several weeks of treatment. Some improvements in body composition markers were observed, though the trial program did not advance to phase 3.
GH Deficiency Context
The development interest was partly in replacing or supplementing recombinant HGH therapy with a longer-acting GHRH analog. By stimulating natural GH production rather than delivering exogenous HGH, the compound works with the body's regulatory mechanisms rather than bypassing them.
Phase 1/2 human trials confirmed sustained GH and IGF-1 elevation lasting several days after a single injection.
Body composition improvements were observed in phase 2 data over a multi-week treatment period.
The DAC technology successfully extends the effective half-life of the GHRH peptide significantly.
Development did not advance to phase 3, and no approved product resulted from the trial program.
CJC-1295 with DAC is not FDA-approved and development did not reach phase 3. The long half-life means that effects — both beneficial and undesired — persist for days to weeks after dosing, which limits the ability to quickly adjust if side effects occur. Long-term effects of sustained GH elevation through this mechanism are not established. Purity and authenticity of research-grade material are important considerations.
Your pituitary gland releases growth hormone in pulses when it receives a signal from GHRH, a hormone made in the hypothalamus. Natural GHRH breaks down in minutes. CJC-1295 with DAC is a GHRH analog with a chemical modification that allows it to bind to albumin in the blood — a protein that acts like a slow-release reservoir. Instead of being broken down in minutes, the compound slowly releases from albumin and keeps stimulating the pituitary over many days. The result is that growth hormone pulses continue to occur at a higher than normal baseline for an extended period after a single dose.
Not FDA-approved. Effects on growth hormone and IGF-1 levels are real and measurable, and the risks associated with elevated growth hormone — including insulin resistance, fluid retention, joint discomfort, and potential effects on cell growth over time — apply. The extended duration of action means side effects cannot be quickly resolved by stopping dosing. Research use requires understanding of these considerations.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
1–2mg weekly in research publications
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
CJC-1295, a Long-Acting GHRH Analogue, Produces Sustained Increases in GH and IGF-1 Levels
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men
Invited review: Recommendations for reporting intervention studies on reproductive performance in dairy cattle: Improving design, analysis, and interpretation of research on reproduction
Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.